Abstract
Lung cancer is the leading cause of cancer related deaths worldwide. The prevalence and frequent deaths associated with lung cancer are due in part to the lack of efficient methods to diagnose the disease progression at an early stage and lack of effective novel treatment strategies. Both genetic and epigenetic mechanisms coordinate in the regulation of transcription which in turn works in regulation of cell growth and proliferation. Numerous genetic and epigenetic changes have been found to be associated with the lung carcinogenesis. The genetic changes include chromosomal abnormalities, oncogene overexpression, mutations in the tumor suppressor genes, changes in DNA repair genes, microsatellite instability, changes in telomerase activity and retrotransposition. These genetic changes either alone or in combination with epigenetic modifications associated with lung cancers such as DNA methylation, histone modifications including histone acetylation and methylation as well as substitution by histone variants have been well studied in lung tumorigenesis. The current review also focuses to address the novel drugs being used in trials such as erlotinib, gefitinib, cetuximab and crizotinib in genetic therapy. Further, a combination of azacitidine, a DNA methyltransferases inhibitor, and entinostat, a histone deacetylases inhibitor, has shown important progress in combined epigenetic therapy against lung tumorigenesis. However, further in depth investigations could identify potential drugs against various types of lung cancer.
Keywords: Epigenetics, lung cancer, DNA methylation, histone modifications, chromosomal abnormalities, microsatellite instability.
Current Cancer Therapy Reviews
Title:Genetics and Epigenetics of Lung Cancer: Mechanisms and Future Perspectives
Volume: 9 Issue: 2
Author(s): Samriddhi Shukla, Sajid Khan, Trygve O. Tollefsbol and Syed M. Meeran
Affiliation:
Keywords: Epigenetics, lung cancer, DNA methylation, histone modifications, chromosomal abnormalities, microsatellite instability.
Abstract: Lung cancer is the leading cause of cancer related deaths worldwide. The prevalence and frequent deaths associated with lung cancer are due in part to the lack of efficient methods to diagnose the disease progression at an early stage and lack of effective novel treatment strategies. Both genetic and epigenetic mechanisms coordinate in the regulation of transcription which in turn works in regulation of cell growth and proliferation. Numerous genetic and epigenetic changes have been found to be associated with the lung carcinogenesis. The genetic changes include chromosomal abnormalities, oncogene overexpression, mutations in the tumor suppressor genes, changes in DNA repair genes, microsatellite instability, changes in telomerase activity and retrotransposition. These genetic changes either alone or in combination with epigenetic modifications associated with lung cancers such as DNA methylation, histone modifications including histone acetylation and methylation as well as substitution by histone variants have been well studied in lung tumorigenesis. The current review also focuses to address the novel drugs being used in trials such as erlotinib, gefitinib, cetuximab and crizotinib in genetic therapy. Further, a combination of azacitidine, a DNA methyltransferases inhibitor, and entinostat, a histone deacetylases inhibitor, has shown important progress in combined epigenetic therapy against lung tumorigenesis. However, further in depth investigations could identify potential drugs against various types of lung cancer.
Export Options
About this article
Cite this article as:
Shukla Samriddhi, Khan Sajid, Tollefsbol O. Trygve and Meeran M. Syed, Genetics and Epigenetics of Lung Cancer: Mechanisms and Future Perspectives, Current Cancer Therapy Reviews 2013; 9 (2) . https://dx.doi.org/10.2174/15733947113099990002
DOI https://dx.doi.org/10.2174/15733947113099990002 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Advancements in Lipid Nanoparticle Delivery Systems for mRNA Therapeutics
The thematic issue will focus on key areas such as lipid nanoparticles, mRNA therapeutics, drug delivery systems, nanotechnology in medicine, targeted therapy, non-viral vectors, precision medicine, and biomedical engineering.read more
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Seeking the 5th Base of DNA Using Chromatographic Methods of Analysis
Current Organic Chemistry A Review on Exploring Better Safety Prospects in Managing Cancer using Liposomal Combinations of Food Bioactive Compounds and Anticancer Drugs: Combisomes
Current Drug Delivery Non-Viral Delivery of RNA Interference Targeting Cancer Cells in Cancer Gene Therapy
Current Gene Therapy Emerging Multi-cancer Regulatory Role of ESRP1: Orchestration of Alternative Splicing to Control EMT
Current Cancer Drug Targets Telomerase Inhibitors: Potential Anticancer Agents
Mini-Reviews in Organic Chemistry Chondroitin Sulphate Decorated Polymeric Nanoparticles: An Effective Carrier for Enhancement of Lung Cancer Targeting Capabilities of Anticancer Drug
Current Nanomedicine Self-immolative Linkers in Prodrugs and Antibody Drug Conjugates in Cancer Treatment
Recent Patents on Anti-Cancer Drug Discovery Role of Serum and Glucocorticoid-Inducible Kinase (SGK)-1 in Senescence: A Novel Molecular Target Against Age-Related Diseases
Current Medicinal Chemistry Glycosylation of Tetraspanin Tspan-1 at Four Distinct Sites Promotes Its Transition Through the Endoplasmic Reticulum
Protein & Peptide Letters Inhibitors of Lactate Dehydrogenase Isoforms and their Therapeutic Potentials
Current Medicinal Chemistry Therapeutic Applications of Mesenchymal Stem Cells: A Comprehensive Review
Current Stem Cell Research & Therapy An Analysis of the Practicalities of Multi-Color Nanoparticle Cellular Bar-Coding
Combinatorial Chemistry & High Throughput Screening Therapeutic Potential of Host Defense Peptides in Antibiotic-resistant Infections
Current Pharmaceutical Design Patents on Immunotoxins and Chimeric Toxins for the Treatment of Cancer
Recent Patents on Drug Delivery & Formulation Mini-Review: Bmx Kinase Inhibitors for Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Functional and Clinical Significance of the Integrin Alpha Chain CD49d Expression in Chronic Lymphocytic Leukemia
Current Cancer Drug Targets Regulation of Angiogenesis by Macrophages, Dendritic Cells, and Circulating Myelomonocytic Cells
Current Pharmaceutical Design Herpes Simplex Virus Type 1 Amplicons and their Hybrid Virus Partners, EBV, AAV, and Retrovirus
Current Gene Therapy 4-Oxothiazolidines with Exocyclic C=C Double Bond(s): Synthesis, Structure, Reactions and Biological Activity
Current Organic Chemistry Inhibition of Pyruvate Dehydrogenase Kinase as a Therapeutic Strategy against Cancer
Current Topics in Medicinal Chemistry